Qian Ao, Zhou Jing, Zhang Xin, Yu Jiaojiao, Wang Xiaoshu
Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Surg. 2023 Jan 5;9:1065316. doi: 10.3389/fsurg.2022.1065316. eCollection 2022.
Recurrence of Rathke's cleft cyst (RCC) is not uncommon after surgery, and the associated factors and incidence of relapse deserve a systematic summary.
This study was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. The Pubmed, Embase, Cochrane, and Web of Science databases were searched until September 12, 2022. Studies with significant results of recurrent factors or specific incidences of RCC recurrence and mean/median follow-up time were included. Based on a protocol of a 2-year interval grouping, included studies were categorized into four groups with follow-up periods <24 months, 24-48 months, 48-72 months, and ≥72 months, respectively. Quality assessment was performed using the NOS score. Pooled estimations were computed by using a random-effects model in the STATA "metaprop" command. Publication bias was assessed visually through a funnel plot and statistically through Egger's linear regression test and Begg's correlation test.
A total of 44 studies were included containing 2,539 cases. Squamous metaplasia was the most commonly reported factor, followed by the extent of cyst removal. The other factors were reported individually. The pooled overall incidences of RCC recurrence after surgery in four groups of the follow-up period were 7.4% (95%CI = 4.1-11.3%) in <24 months, 13.1% (95%CI = 9.7-17.0%) in 24-48 months, 13.7% (95%CI = 7.7-21.0%) in 48-72 months, and 33.8% (95%CI = 19.6-49.6%) in ≥72 months. The pooled symptomatic incidences were 2.3% (95%CI = 0.4-5.1%) in <24 months, 5.6% (95%CI = 3.6-7.9%) in 24-48 months, 5.9% (95%CI = 2.4-10.6%) in 48-72 months, and 14.1% (95%CI = 6.0-24.5%) in ≥72 months. A dramatic increase in recurrent incidence was observed when the follow-up period was more than 72 months in both overall and symptomatic recurrence. A similar trend of recurrence was found in subgroup analyses stratified by publication year, cohort size, and cyst resection strategy.
This study systematically reviewed recurrent factors and described the profile of trends in RCC recurrent incidence after surgery with a follow-up time based on a protocol of a 2-year interval, finding a dramatic increase in recurrent rates with a follow-up period of more than 72 months. This encouraged us to put forward a recommendation of at least a 6-year follow-up after surgery for patients with RCC.
https://www.crd.york.ac.uk/prospero/, identifier: CRD42021278970.
拉克氏囊肿(RCC)术后复发并不少见,其相关因素及复发率值得系统总结。
本研究按照系统评价与Meta分析的首选报告项目(PRISMA)指南进行。检索了Pubmed、Embase、Cochrane和Web of Science数据库,检索截至2022年9月12日。纳入具有RCC复发因素显著结果或RCC复发的特定发生率以及平均/中位随访时间的研究。基于2年间隔分组方案,将纳入研究分为四组,随访期分别为<24个月、24 - 48个月、48 - 72个月和≥72个月。使用NOS评分进行质量评估。采用STATA“metaprop”命令中的随机效应模型计算合并估计值。通过漏斗图直观评估发表偏倚,并通过Egger线性回归检验和Begg相关性检验进行统计学评估。
共纳入44项研究,包含2539例病例。鳞状化生是最常报道的因素,其次是囊肿切除范围。其他因素则单独报道。随访期四组术后RCC复发的合并总体发生率在<24个月时为7.4%(95%CI = 4.1 - 11.3%),24 - 48个月时为13.1%(95%CI = 9.7 - 17.0%),48 - 72个月时为13.7%(95%CI = 7.7 - 21.0%),≥72个月时为33.8%(95%CI = 19.6 - 49.6%)。合并有症状发生率在<24个月时为2.3%(95%CI = 0.4 - 5.1%),24 - 48个月时为5.6%(95%CI = 3.6 - 7.9%),48 - 72个月时为5.9%(95%CI = 2.4 - 10.6%),≥72个月时为14.1%(95%CI = 6.0 - 24.5%)。在总体和有症状复发中,当随访期超过72个月时,复发率均显著增加。在按发表年份、队列规模和囊肿切除策略分层的亚组分析中发现了类似的复发趋势。
本研究系统回顾了复发因素,并基于2年间隔方案描述了RCC术后复发率随随访时间的变化情况,发现随访期超过72个月时复发率显著增加。这促使我们对RCC患者术后提出至少6年随访的建议。